Home » Topics » Respiratory, BioWorld Science

Respiratory, BioWorld Science
RSS

Eisai's ER-27319: Potential in treating allergic diseases

June 28, 1996

GCC-AP0341: Green Cross' eosinophilia inhibitor

June 28, 1996

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

June 28, 1996

Abbott discloses 5-lipoxygenase inhibitors

June 28, 1996

Leukotriene biosynthesis inhibitors from Merck Frosst

June 28, 1996

Proctor & Gamble acquires Dura products

June 28, 1996

Thymosin beta4 as cystic fibrosis treatment

June 21, 1996

Astra's Pulmicort approaches FDA approval

June 21, 1996

B2 antagonists from Servier

June 21, 1996

Ono reveals antioxidant TxA2 synthase/5-lipoxygenase inhibitors

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...